Hormonal
GLP-1 receptor agonists (e.g., Liraglutide, Semaglutide) and dual/triple agonists are highly effective for weight loss and diabetes remission, acting on both homeostatic and hedonic appetite pathways, but require continuous use to maintain effects.
GLP-1 medications (like Semaglutide or Liraglutide) are highly effective for significant weight loss and diabetes remission, often working better than diet alone. They work by reducing both physical hunger and the 'craving' for food. However, they must be taken continuously; stopping them usually leads to weight regain. Discuss with your doctor if you are a candidate, considering the cost and injection requirement.
GLP-1과 GIP 병합제재 10 mg에서 82%의 HbA1c <6.5%의 당뇨병 완화를, 또한 15 mg에서 30.2%의 HbA1c <5.7%의 당뇨병 완화 결과를 보여 향후 최종 임상 결과가 기대된다... 약 중단 시 체중 재증가(yoyo) 및 혈당 억제 효과가 바로 감소하는 것이다.
Why this rating
Based on Phase II/III clinical trials and large-scale studies (SCALE, LEADER) cited in the review.
Source
Current Treatments on Obesity
Chul Jin Lee et al. · Daehan imsang geon-gang jeungjin hakoeji/Daehan imsang geon'gang jeungjin haghoeji · 2019
DOI 10.15384/kjhp.2019.19.4.171
More from this paper
- A primary care-led, very-low-calorie diet (825-853 kcal/day) can induce remission of type 2 diabetes, with remission rates directly correlating to the magnitude of weight loss (86% remission with >15% weight loss).Good
- Long-term adherence to a Low-Carb High-Fat (LCHF) diet is difficult for most patients, leading to decreased efficacy over time compared to low-fat diets, although it may offer short-term benefits for diabetes management.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →